Clarity Receives US FDA response on its Theranostic Investigational New Drug (IND) Application that the study may proceed
Sydney, Australia 3 October 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that it has received a response on its Investigational New Drug (IND) application that the study may proceed from the U.S. Food and Drug Administration (FDA) for a Phase 1-2a theranostic (i.e. diagnostic…